FGF2 and benign prostatic hyperplasia: Androgen responsive promoter sequences, androgen-induced cre recombinase or viral promoters are used to target genetic modifications to mouse prostate tissue and overexpress fibroblast growth factor 2 or fibroblast growth factor 3 to drive epithelial BPH [187,188,189], overexpress prolactin [190,191,192,193] or interleukin 1 alpha [194] to drive epithelial and stromal BPH and prostate inflammation, delete serine/threonine kinase 11 to promote stromal BPH in the periurethral region [195], or genetically modify other sequences.